Skip to main content

Seattle biotech Impel NeuroPharma raises $80M in IPO

The market for migraine treatments, which the company develops, is expected to triple in size to more than $10 billion by 2028, it said in a public filing.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.